Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 September 2004

Comparative investigation of the safety of hexavalent vaccines for primary scheduled infant immunizations in Germany over a time period of 2 years

Gerd M. Lackmann

Med Sci Monit 2004; 10(9): PI96-98 :: ID: 11759

Abstract

Background:Confidence in hexavalent vaccines has recently been shattered in Germany, after 5 infant deaths occurred shortly after such a vaccination. The aim of this study was to evaluate the safety of hexavalent vaccines over a time period of 2 years.Material/Methods: With the written informed consent of the parents, we enrolled in the study all healthy infants who attended our office for a primary scheduled infant immunization during the study period from July 1, 2001, to June 30, 2003. This period was divided into two parts: (1) In a pilot study (July 1 to December 31, 2001), the two hexavalent vaccines licensed in Germany, Hexavac[sup]®[/sup] and Infanrix hexa[sup]®[/sup], were compared to each other to evaluate if one of these vac­cines would be better tolerated. (2) During the follow-up study period (January 1, 2002, to June 30, 2003), that hexavalent vaccine was to be used, if any, which had been shown to have lower side effects during the pilot period. The trivalent measles-mumps-rubella vaccine Priorix[sup]®[/sup] was applied to all infants during both study periods. The parents were advised to im­mediately consult our office in any case of suspected or proven side effect from the vaccination.Results: 3658 polyvalent (hexavalent and trivalent) vaccinations were applied to 1997 infants. Local reactions were observed after application of Priorix[sup]®[/sup] in 0.0%, of Infanrix hexa[sup]®[/sup]. in 0.46%, and of Hexavac[sup]®[/sup] in 3.1%, respectively.Conclusions: The safety of Priorix[sup]®[/sup] and Infanrix hexa[sup]®[/sup] in particular could be established. Hexavalent vaccines can be recommended for introduction in all European countries for primary scheduled infant immunizations.

Keywords: Vaccines, Combined - adverse effects, Vaccines, Combined - chemistry, Vaccines, Combined - immunology, Vaccines, Combined - therapeutic use, Germany, Pilot Projects, Vaccines, Combined - therapeutic use

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750